Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Dr. Matulonis on the Use of Immunotherapy in Recurrent Ovarian Cancer

January 11th 2019

Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the use of immunotherapy in patients with recurrent ovarian cancer.

Dr. Rana on Genetic Testing Guidelines for Patients With Ovarian Cancer

January 9th 2019

Huma Q. Rana, MD, clinical director, Cancer Genetics and Prevention, instructor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses genetic testing guidelines for patients with ovarian cancer.

Dr. Liu on the Use of Bevacizumab in Newly Diagnosed Advanced Ovarian Cancer

January 8th 2019

Joyce F. Liu, MD, MPH, assistant professor of medicine and director of clinical research for gynecologic oncology at Dana-Farber Cancer Institute, discusses the use of bevacizumab (Avastin) in the treatment of patients with newly diagnosed advanced ovarian cancer.

HPV Subtypes Linked to Development of High-Grade Cervical Cancer

January 4th 2019

The presence of specific subtypes of HPV, namely HPV-16 and -18, were found to be associated with a higher risk of developing high-grade cervical intraepithelial neoplasia in women under the age of 30.

Added Factors Put the Overall Survival Endpoint to the Test

January 3rd 2019

The impact of subsequent lines of treatment on trial outcomes can be substantial, seriously challenging the relevance of OS as an objectively meaningful study endpoint.

Dr. English on Mirvetuximab Soravtansine in Ovarian Cancer

December 20th 2018

Diana P. English, MD, a gynecologic oncologist at Stanford Hospital and Clinics, discusses the development of the antibody drug conjugate (ADC) mirvetuximab soravtansine in ovarian cancer.

Potential Risks of Genetic Testing in Ovarian Cancer

December 15th 2018

Peter Levonian, MS, senior genetic counselor, Stanford Medicine, discusses the potential risks of genetic testing in ovarian cancer.

EU Panel Backs Maintenance Rucaparib for Ovarian Cancer

December 14th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended to expand the approval of single-agent rucaparib as a maintenance therapy in adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

New Strategies Are Needed as Ovarian Cancer Becomes a Chronic Disease

December 10th 2018

Since the introduction of platinum agents in ovarian cancer, it is reasonable to suggest there have been only limited changes in the basic paradigm of ovarian cancer management over the past several decades.

Dr. Makker on Safety Signals With Lenvatinib and Pembrolizumab in Endometrial Cancer

November 30th 2018

Vicky Makker, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses safety signals with the combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) in endometrial cancer.

Amid Mixed Data, Immunotherapy Remains a Focal Point in Ovarian Cancer

November 27th 2018

Oliver Dorigo, MD, PhD, discusses the promise of immunotherapy in ovarian cancer.

PARP Inhibitors Continue to Lead Progress in Ovarian Cancer

November 26th 2018

Elisabeth Diver, MD, discusses ongoing advances with PARP inhibitors in ovarian cancer.

Dr. Makker on Combination Approaches in Endometrial Cancer

November 16th 2018

Vicky Makker, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses combination approaches garnering interest in endometrial cancer.

Dr. Nguyen on Treatment Approaches for Patients With Advanced Ovarian Cancer

November 14th 2018

Trung Nguyen, DO, MBA, clinical assistant professor, Obstetrics and Gynecology, Gynecologic Oncology, Stanford Medicine, discusses treatment approaches for patients with advanced ovarian cancer.

Dr. Dorigo on Immunotherapy in Ovarian Cancer

November 13th 2018

Oliver Dorigo, MD, PhD, associate professor of Obstetrics and Gynecology, Stanford University Medical Center, Stanford Medicine, discusses the use of immunotherapy in the treatment of patients with ovarian cancer.

Dr. Rischin Discusses the Future of Cemiplimab in Cervical Cancer

November 13th 2018

Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, discusses the next steps with cemiplimab (Libtayo) in the treatment landscape of cervical cancer.

Lurbinectedin Does Not Improve PFS in Platinum-Resistant Ovarian Cancer

November 12th 2018

Results of the phase III CORAIL trial demonstrated that the marine-derived treatment lurbinectedin did not improve progression-free survival compared with pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer.

Dr. Ganjoo on Therapies for Patients With Uterine Leiomyosarcomas

November 9th 2018

Kristen N. Ganjoo, MD, associate professor of medicine, Stanford University Medical Center, Stanford Medicine, discusses therapies for patients with uterine leiomyosarcomas.

Real-World Data With Niraparib Show Lower AEs Vs ENGOT-OV6/NOVA Trial in Ovarian Cancer

November 8th 2018

Real-world incidences of nausea, thrombocytopenia, and fatigue were markedly lower in patients with platinum-sensitive, recurrent ovarian cancer receiving a starting 200-mg daily dose of niraparib versus those enrolled on the phase III ENGOT-OV6/NOVA trial.

PFS Improved With Maintenance Rucaparib in Recurrent Ovarian Cancer Irrespective of Prior Chemo

November 7th 2018

In patients with platinum-sensitive recurrent ovarian cancer, the PARP inhibitor rucaparib as maintenance treatment improved progression-free survival versus placebo, despite the number of chemotherapy regimens.